Provided by Tiger Trade Technology Pte. Ltd.

Global Partners LP

46.94
-0.3400-0.72%
Post-market: 47.200.2600+0.55%19:46 EST
Volume:46.40K
Turnover:2.19M
Market Cap:1.60B
PE:22.56
High:47.75
Open:47.50
Low:46.69
Close:47.28
52wk High:60.00
52wk Low:39.58
Shares:34.00M
Float Shares:27.67M
Volume Ratio:1.29
T/O Rate:0.17%
Dividend:2.99
Dividend Rate:6.37%
EPS(TTM):2.08
EPS(LYR):2.41
ROE:13.77%
ROA:3.98%
PB:2.63
PE(LYR):19.48

Loading ...

Dow Jones Top Company Headlines at 7 PM ET: FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs | Justice ...

Dow Jones
·
15 hours ago

FDA intends to ‘take action’ against non-FDA-approved GLP-1 drugs

TIPRANKS
·
17 hours ago

Embecta: Stable Execution, GLP-1–Driven Growth Optionality, and Attractive Valuation Support Buy Rating and $25 Target

TIPRANKS
·
Yesterday

LifeVantage Earnings Call: GLP-1 Hit Tests Turnaround

TIPRANKS
·
Yesterday

Edible Garden to Participate in ECRM’s Total Wellness: GLP-1, Weight Management, Nutrition & Vitamin Session, February 10–12, 2026

GlobeNewswire
·
Feb 05

Press Release: GLP China Holdings Limited TENDER OFFER TO PURCHASE FOR CASH ANY AND ALL OF ITS U.S.$700,000,000 2.95 PER CENT. NOTES DUE 2026

Dow Jones
·
Feb 05

PepsiCo Charts Growth Amid GLP-1, Ad Headwinds

TIPRANKS
·
Feb 04

Is It Time To Reassess Global Partners (GLP) After Big Five Year Share Gains?

Simply Wall St.
·
Jan 31

Press Release: Global Partners Declares Fourth-Quarter 2025 Cash Distribution of $0.7600 on Common Units

Dow Jones
·
Jan 30

Fractyl Health Advances Revita for Post-GLP-1 Weight Maintenance

TIPRANKS
·
Jan 29

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

GlobeNewswire
·
Jan 28

Huadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market

Deep News
·
Jan 27

Roche Reports Positive Phase II Trial Results for GLP-1/GIP Dual Receptor Drug

Deep News
·
Jan 27

ASCLETIS-B (01672) Announces Completion of First Dosing in 13-Week US Phase II Study of Oral Small-Molecule GLP-1R Agonist ASC30 for Diabetes

Stock News
·
Jan 26

Ascletis Starts U.S. Phase II Diabetes Trial of Oral GLP-1 Drug ASC30 After Strong Obesity Data

TIPRANKS
·
Jan 26

ASCLETIS-B (01672) Selects Next-Generation Monthly Subcutaneous GLP-1R/GIPR/GCGR Triple Agonist Peptide ASC37 for Clinical Development

Stock News
·
Jan 20

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

prnewswire
·
Jan 20

PolyPeptide lifts revenue and margins in 2025 as GLP-1 demand powers growth

TIPRANKS
·
Jan 19

Net Profit Expected to Surge Over 200%, Sheng Nuo Biotec Feasts on GLP-1 Weight-Loss Market Boom

Deep News
·
Jan 16

Hybio Pharmaceutical Sells GLP-1 Raw Materials for Slimming Products

MT Newswires Live
·
Jan 16